Drugs / HCP1904-2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04830449 | Oct 2020 → Aug 2021 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCP1904-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04830449 ↗ |
| Route | Oral | “Take it once daily for 8 weeks orally.” NCT04830449 ↗ |